市場調査レポート
商品コード
1451625
バイオマーカー市場レポート:製品タイプ、疾患、用途、エンドユーザー、地域別、2024-2032Biomarkers Market Report by Product, Type, Disease, Application, End User, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
バイオマーカー市場レポート:製品タイプ、疾患、用途、エンドユーザー、地域別、2024-2032 |
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2~3営業日
|
バイオマーカーの世界市場規模は2023年に799億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて11.37%の成長率(CAGR)を示し、2032年までに2,207億米ドルに達すると予測しています。慢性疾患の増加、バイオテクノロジーとゲノミクスの継続的な発展、個別化医療へのシフト、分析技術の継続的な進歩、バイオマーカーの利点に関するヘルスケア専門家と患者の両方の意識の高まりは、市場を推進する主な要因のいくつかです。
バイオマーカーは人体内で測定可能な指標であり、様々な生物学的プロセスや状態に関する重要な情報を提供します。バイオマーカーには、タンパク質、遺伝子、ホルモン、あるいは身体的特徴など、さまざまな物質が含まれます。バイオマーカーは医学研究、診断、治療計画において重要な役割を果たしています。バイオマーカーによって、ヘルスケア専門家や研究者は、病気の有無や進行を評価したり、治療の効果をモニターしたり、特定の健康問題に対する個人の感受性を予測したりすることができます。市場調査やコンサルティングサービスの領域では、バイオマーカーの理解は極めて重要であり、ヘルスケアや製薬業界の意思決定プロセスを導き、革新的なソリューションや戦略の開発に役立っています。
がん、心血管疾患、糖尿病などの慢性疾患の増加は、世界全体の市場成長を促進する重要な要因の一つです。早期発見、疾患モニタリング、個別化治療戦略の開発に不可欠です。バイオテクノロジーとゲノミクスの継続的な進歩により、新規バイオマーカーの発見が進み、診断、医薬品開発、精密医療への応用が拡大しています。バイオマーカーは、標的同定、薬剤候補の有効性評価、安全性プロファイリングに役立ち、製薬研究にとって不可欠です。これによって医薬品開発が加速し、コストが削減され、成功率が高まる。個別化医療へのシフトは、個々の患者のプロファイルに合わせて治療計画を調整し、治療成績を向上させ、副作用を最小限に抑えるために、バイオマーカーに大きく依存しています。高齢者は慢性疾患にかかりやすいため、バイオマーカーによる早期発見と効果的な管理が必要となります。ゲノミクス、プロテオミクス、イメージングなどの分析技術の絶え間ない改善により、バイオマーカー検出の感度と特異性が向上し、その応用範囲が広がっているため、バイオマーカー市場の成長は世界中で促進されています。
疾病負担とヘルスケアコストの増加
バイオマーカー市場の主な促進要因の1つは、世界の疾病負担の増大であり、特にがん、心血管疾患、糖尿病などの慢性疾患が顕著です。バイオマーカーはこれらの疾患の早期発見、診断、モニタリングにおいて極めて重要な役割を果たしています。バイオマーカーによって、ヘルスケア専門家は病気のリスクを特定し、治療戦略を立て、治療反応をより効果的に追跡することができます。ヘルスケアシステムが、増加する疾病負担を管理するという課題に直面する中、バイオマーカーは、早期介入や標的治療を通じて患者の転帰を改善し、医療費を削減するための貴重なツールとなります。
バイオテクノロジーと個別化医療の著しい進歩
ゲノミクス、プロテオミクス、ハイスループットスクリーニングを含むバイオテクノロジーツールや技術の絶え間ない進歩は、バイオマーカーの発見と検証に革命をもたらしました。その結果、高い特異性と感度を持つ新規バイオマーカーが同定され、診断と予後の能力が向上しました。さらに、個別化医療へのパラダイムシフトは、個々の患者のプロファイルに合わせた治療を行うためのバイオマーカーに大きく依存しています。バイオマーカー主導のアプローチにより、ヘルスケアプロバイダーは最適な治療法を選択することが可能となり、治療効果を高め、副作用を最小限に抑えることができます。これにより、患者の治療が改善されるだけでなく、バイオマーカーに基づく検査や治療に対する需要も高まっています。
医薬品開発と臨床試験の増加
バイオマーカーは製薬業界において不可欠なものとなりつつあり、創薬と薬剤開発を促進しています。バイオマーカーは、標的の同定、臨床試験における患者の層別化、薬剤の有効性と安全性の評価を容易にします。その結果、医薬品開発プロセスが合理化され、コストが削減され、新薬の上市成功率が高まる。FDAやEMAなどの規制機関は、医薬品承認におけるバイオマーカーの重要性をますます認識するようになっており、臨床試験や医薬品開発パイプラインへのバイオマーカーの統合をさらに加速させています。
The global biomarkers market size reached US$ 79.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 220.7 Billion by 2032, exhibiting a growth rate (CAGR) of 11.37% during 2024-2032. The rising prevalence of chronic diseases, ongoing developments in biotechnology and genomics, the shift toward personalized medicine, continuous advancements in analytical technologies, and increasing awareness among both healthcare professionals and patients about the benefits of biomarkers are some of the major factors propelling the market.
Biomarkers are measurable indicators within the human body that provide essential information about various biological processes and conditions. These markers can encompass a wide range of substances, including proteins, genes, hormones, or even physical characteristics. Biomarkers play a crucial role in medical research, diagnosis, and treatment planning. They enable healthcare professionals and researchers to assess the presence or progression of diseases, monitor the effectiveness of therapies, and predict an individual's susceptibility to certain health issues. In the realm of market research and consulting services, understanding biomarkers is pivotal, as they guide decision-making processes in healthcare and pharmaceutical industries, aiding in the development of innovative solutions and strategies.
The rise in chronic diseases, including cancer, cardiovascular disorders, and diabetes, represents one of the key factors driving the growth of the market across the globe. They are indispensable for early detection, disease monitoring, and the development of personalized treatment strategies. The continuous progress in biotechnology and genomics is leading to the discovery of novel biomarkers, expanding their applications across diagnostics, drug development, and precision medicine. Biomarkers are integral to pharmaceutical research, assisting in target identification, drug candidate efficacy evaluation, and safety profiling. This accelerates drug development, reduces costs, and enhances success rates. The shift towards personalized medicine relies heavily on biomarkers to tailor treatment plans to individual patient profiles, improving treatment outcomes and minimizing side effects. The globally aging population is a key driver, as elderly individuals are more prone to chronic diseases, necessitating early detection and effective management using biomarkers. Continuous improvements in analytical technologies, such as genomics, proteomics, and imaging enhance the sensitivity and specificity of biomarker detection, which is broadening their applications, thus facilitating the market growth across the globe.
Rising disease burden and healthcare costs
One of the primary drivers of the biomarkers market is the escalating global burden of diseases, particularly chronic conditions like cancer, cardiovascular diseases, and diabetes. Biomarkers play a pivotal role in the early detection, diagnosis, and monitoring of these diseases. They enable healthcare professionals to identify disease risks, formulate treatment strategies, and track treatment responses more effectively. As healthcare systems face the challenge of managing these increasing disease burdens, biomarkers provide a valuable tool for improving patient outcomes and reducing healthcare costs through early intervention and targeted therapies.
Significant advancements in biotechnology and personalized medicine
The continuous advancement of biotechnological tools and techniques, including genomics, proteomics, and high-throughput screening, has revolutionized biomarker discovery and validation. This has led to the identification of novel biomarkers with high specificity and sensitivity, enhancing their diagnostic and prognostic capabilities. Moreover, the paradigm shift towards personalized medicine relies heavily on biomarkers to tailor treatments to individual patient profiles. Biomarker-driven approaches enable healthcare providers to select the most suitable therapies, thereby increasing treatment efficacy and minimizing adverse effects. This has not only improved patient care but has also intensified the demand for biomarker-based tests and therapies.
Rise in drug development and clinical trials
Biomarkers are becoming indispensable in the pharmaceutical industry, which is driving drug discovery and development, thus acting as a major growth-inducing factor. They facilitate target identification, patient stratification for clinical trials, and assessment of drug efficacy and safety. This results in streamlined drug development processes, reduced costs, and increased success rates in bringing new drugs to market. Regulatory agencies, such as the FDA and EMA, increasingly recognize the significance of biomarkers in drug approvals, which is further accelerating their integration into clinical trials and drug development pipelines.
IMARC Group provides an analysis of the key trends in each segment of the global biomarkers market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, type, disease, application, and end user.
Consumables
Services
Software
Consumables dominate the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes consumables, services, and software. According to the report, consumables represented the largest segment.
The demand for consumables in the biomarkers market is driven by several influential factors. Primarily, the continuous expansion of biomarker research in various fields, including oncology, cardiology, and neuroscience, necessitates a steady supply of consumables. Researchers rely on consumables such as assay kits, reagents, and laboratory supplies to conduct experiments and validate biomarkers for clinical applications. The growing adoption of biomarkers for clinical diagnostics fuels demand for consumables used in diagnostic tests. Consumables like test kits, sample collection devices, and assay reagents are essential for accurate biomarker-based diagnosis, enabling early disease detection and monitoring. Biomarkers are integral to drug discovery and development, where consumables like cell culture media, plates, and assay components are essential. The pharmaceutical industry's robust pipeline of biomarker-driven therapies and the need for large-scale screening drive demand for consumables. The trend towards personalized medicine, which relies on biomarkers for treatment tailoring, has increased the need for consumables. Customized therapies based on individual biomarker profiles require specific consumables for their development and administration.
Efficacy Biomarkers
Safety Biomarkers
Validation Biomarkers
Safety biomarkers hold the largest share in the market
The report has provided a detailed breakup and analysis of the market based on the type. This includes efficacy biomarkers, safety biomarkers, and validation biomarkers. According to the report, safety biomarkers represented the largest segment.
The demand for safety biomarkers in the biomarkers industry is influenced by several critical factors. Regulatory agencies, such as the FDA and EMA, mandate the evaluation of safety biomarkers in drug development to assess potential adverse effects and toxicity. Compliance with these regulations drives the demand for safety biomarker assays and testing services. The high costs associated with drug development, including the expenses incurred due to adverse events and late-stage failures, underscore the importance of safety biomarkers. Early detection of safety concerns can significantly reduce development expenses, prompting the pharmaceutical industry to invest in safety biomarker research and implementation. Ensuring patient safety is paramount in clinical trials. The utilization of safety biomarkers helps identify and mitigate potential risks to participants, aligning with ethical and safety considerations. Technological advancements, such as omics technologies (genomics, proteomics, metabolomics), enable the discovery of novel safety biomarkers with enhanced sensitivity and specificity. The availability of cutting-edge tools and assays drives the adoption of safety biomarkers in drug safety assessment.
Cancer
Cardiovascular Disorders
Neurological Disorders
Immunological Disorders
Renal Disorders
Others
Cancer dominates the market
The report has provided a detailed breakup and analysis of the market based on the disease. This includes cancer, cardiovascular disorders, neurological disorders, immunological disorders, renal disorders, and others. According to the report, cancer represented the largest segment.
Biomarkers play a pivotal role in cancer research, diagnosis, treatment, and patient management. Their applications in cancer are multifaceted and essential. Primarily, biomarkers enable the early detection of cancer, often before symptoms manifest. Blood-based biomarkers, such as circulating tumor DNA (ctDNA) and specific proteins like PSA (Prostate-Specific Antigen), aid in screening and early diagnosis. Biomarkers help confirm cancer diagnoses and classify tumors into specific subtypes. For instance, hormone receptor status (estrogen and progesterone receptors) in breast cancer guides treatment decisions. Biomarkers provide prognostic information, helping predict the course of the disease. Genetic markers and gene expression profiles assist in estimating a patient's likely outcome and risk of recurrence. Biomarkers guide treatment decisions by identifying targeted therapies. For instance, the presence of HER2/neu in breast cancer indicates eligibility for HER2-targeted therapies like trastuzumab. Biomarkers are used to monitor treatment efficacy and disease progression. Imaging biomarkers, like PET scans, assess tumor response to therapy, aiding treatment adjustments.
Diagnostics
Drug Discovery and Development
Personalized Medicine
Others
Drug discovery and development hold the largest share in the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes diagnostics, drug discovery and development, personalized medicine, and others. According to the report, drug discovery and development represented the largest segment.
Biomarkers are indispensable tools in drug discovery and development, offering several critical applications that streamline the process and increase its efficiency. Biomarkers help identify and validate potential drug targets by providing insights into their role in disease pathways. This ensures that drug development efforts are focused on biologically relevant targets. Biomarkers aid in assessing the effectiveness of drug candidates during preclinical and clinical trials. They provide quantifiable measurements of the drug's impact on the target and its downstream effects, helping to select the most promising candidates. Safety biomarkers are crucial for evaluating the potential adverse effects of drug candidates. They help identify safety concerns early in the development process, reducing the risk of late-stage failures. Biomarkers enable the stratification of patient populations, identifying subgroups that are more likely to respond to a specific treatment. This supports the development of targeted therapies, optimizing treatment outcomes.
Pharmaceutical and Biotechnology Companies
Diagnostic and Research Laboratories
Hospitals and Specialty Clinics
Others
Diagnostic and research laboratories dominates the market
The report has provided a detailed breakup and analysis of the market based on the end user. This includes pharmaceutical and biotechnology companies, diagnostic and research laboratories, hospitals and specialty clinics, and others. According to the report, diagnostic and research laboratories represented the largest segment.
Biomarkers have a significant impact on the operations of diagnostic and research laboratories, serving a wide range of crucial purposes. Biomarkers are fundamental in clinical diagnostics, aiding in the accurate and early diagnosis of various diseases. They provide measurable indicators of disease presence or progression, enhancing diagnostic precision. Biomarkers enable the categorization of patients into different risk groups or disease subtypes, helping healthcare providers tailor treatment plans to individual profiles. In research and clinical settings, biomarkers are used to monitor disease progression and assess the effectiveness of treatments. This helps in disease management and optimization of therapeutic interventions. Laboratories use biomarkers to evaluate drug responses, assess drug metabolism, and understand the relationship between drug dose and effect. Biomarkers play a role in assessing the safety of drugs and therapies and identifying potential side effects and toxicities. Biomarkers serve as key tools in laboratory research, aiding in the discovery of new disease mechanisms, drug targets, and potential therapeutic interventions.
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Russia
Spain
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Russia, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The biomarkers industry in North America is driven by several influential factors that contribute to its growth and development. The high prevalence of chronic diseases, including cancer, cardiovascular disorders, and diabetes, in North America has fueled the demand for biomarkers. Biomarkers are crucial for early detection, monitoring, and treatment selection in these conditions. North America boasts a well-developed healthcare infrastructure, including state-of-the-art laboratories and research facilities. This infrastructure supports biomarker research, development, and implementation. The region is home to a robust biotechnology and pharmaceutical industry. Biomarkers play a central role in drug discovery, development, and clinical trials, driving their demand. Regulatory agencies like the FDA in the United States have recognized the importance of biomarkers in drug development and diagnostics. Clear regulatory pathways for biomarker-based products encourage their use. Significant investments in research and development (R&D), both public and private, support biomarker discovery and validation, enhancing their role in healthcare. Ongoing technological advancements in genomics, proteomics, and diagnostic technologies are improving the accuracy and efficiency of biomarker assays.
Key players in the market are actively engaged in various strategic initiatives to advance research, development, and commercialization in this dynamic field. Leading companies invest heavily in R&D to discover and validate novel biomarkers. They collaborate with academic institutions and research organizations to expand their biomarker portfolios. Many biomarker companies form strategic partnerships with pharmaceutical and biotechnology firms to integrate biomarkers into drug development pipelines. These collaborations aim to identify biomarkers for patient stratification and treatment response prediction. Companies continuously expand their biomarker product portfolios, offering a wide range of assays, kits, and services for diverse applications, from diagnostics to drug development. Leading players invest in cutting-edge technologies, such as next-generation sequencing and mass spectrometry, to enhance the sensitivity and specificity of biomarker detection methods. Some key players focus on developing companion diagnostics, and aligning biomarker tests with specific therapies to ensure precise treatment selection and improve patient outcomes.
Agilent Technologies Inc.
Bio-Rad Laboratories Inc.
Charles River Laboratories International Inc.
Epigenomics AG
Eurofins Scientific SE
Merck KGaA
Perkinelmer Inc.
Qiagen N.V
Quanterix Corporation
SphingoTec GmbH
Thermo Fisher Scientific Inc.
In June 2023, FDA announced a new voluntary pilot program for certain oncology drug products used with certain corresponding in-vitro diagnostic tests. The goal of this program is to help clinicians select appropriate cancer treatments for patients.
In March 2022, Union Health Minister Mansukh Madaviya launched the Diet and Biomarkers Survey in India (DABS-I) at the National Institute of Nutrition (NIN) here on Saturday.
November 30, 2020, Agilent announced launch of global biomarker pathologist training program, designed to enrich pathologists' skills in biomarker interpretation and scoring techniques.